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This study shows that speciﬁc microRNAs differentially regulated by DNp63a in cisplatin-sensitive
and resistant squamous cell carcinoma (SSC) cells of larynx and tongue affect the expression of
members of the necroptotic pathway CYLD, RIPK1, and MLKL. Different degrees of protein interac-
tion between necroptotic signaling intermediates were also observed in SCC cells sensitive or resis-
tant to cisplatin. Modulation of RIPK1 with miR-101-3p mimic or inhibitor, as well as with siRNA, or
chemical inhibitors was shown to affect sensitivity of SCC cells to cisplatin. This is the ﬁrst report
showing the modulatory effect of DNp63a-responsive microRNAs on the speciﬁc members of
necroptotic pathway in SCC tumor cells variably responding to platinum chemotherapy.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Maintaining a tight balance between cell survival and cell death
is pivotal for various normal and pathological conditions [1,2].
Molecular mechanisms underlying the processes leading to cell
death are evolutionarily conserved across species, ranging from
yeast, ﬂies, and worms to mammals and humans, supporting the
importance of these cellular mechanisms for multicellular organ-
isms [1,2]. A main goal of the anti-cancer chemotherapy is to
induce cell death phenotype in tumor cells and to stimulate the
series of molecular events altering the survival of tumor cell up
to their demise [2–4]. Cellular responses to the stress factors ofteninducing DNA damage, oxidative overload, and malfunctions in cell
survival involve multiple signaling pathways [2,3]. These geneti-
cally programmed pathways include cell cycle arrest, apoptosis,
autophagy and necroptosis among others [2–6]. Several proteins
involved in apoptosis or autophagy were shown to participate in
a crosstalk with necroptotic molecular machinery [5–7].
Cisplatin is the most used chemotherapeutic agent to treat
human head and neck cancer because of its ability to induce cell
death, however, tumor cells often developed an acquired resistance
to cisplatin [8]. p53 family members (p53, p63 and p73) are key
transcriptional factors that orchestrate the cellular response to cis-
platin treatment [9–12]. Being at the helm of the transcriptional
regulation, p53 family members actively inﬂuence the levels of
various mRNAs, and subsequently the proteins engaged in multiple
processes of cell death (cell arrest, apoptosis, and autophagy),
especially during tumorigenesis [9–12].
P53 homologue p63 was shown to directly induce the transcrip-
tion of CD95 death receptor (FAS, TNFRSF6), which plays a critical
role in tumor necrosis factor (TNF)-dependent activation of
necroptotic signaling and extrinsic apoptotic signaling [13]. P63-
dependent transcriptional regulation of the TNF and TNF-related
apoptosis-inducing ligand (TRAIL) death receptor’s expression fur-
ther supports a link between mitochondrial apoptoptic and
necroptotic pathways [13,14].
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consist of two groups, including those with the transactivation
(TA)-domain at the amino terminus (TAp63a, TAp63b, and
TAp63c) or those without it (DNp63a, DNp63b, and DNp63c)
[11,12]. Cisplatin treatment was shown to induce the phosphoryla-
tion of the predominant p63 isoform, DNp63a, in cisplatin-
sensitive squamous cell carcinoma cells (SCC-11) by ataxia
telangiectasia mutated (ATM) kinase at the position S385 (SCC-
11M) [15]. We generated the isogeneic SCC cell lines derived from
larynx and expressing the wild type DNp63a (SCC11 cells) or
mutated DNp63a (SCC-11M cells with the altered ability to main-
tain the phosphorylation of DNp63a by ATM kinase) [15–17].
Previous studies have pointed-out that cisplatin-sensitive SCC cells
express exclusively (SCC-11, larynx) or predominantly (SCC-25,
tongue) a phosphorylated (p)-DNp63a protein [18,19]. We further
found that these cell lines differentially express speciﬁc microRNAs
[16–18]. We showed that the speciﬁc DNp63a-responsive
microRNAs are likely to module protein targets involved in cell
cycle arrest, apoptosis or autophagy, and epigenetic regulation
[16–19]. In this report, we would like to emphasize the role for
DNp63a-responsive microRNAs in modulation of members of
necroptotic signaling pathway suggesting that this new genetically
programmed molecular mechanism may contribute to a tumor cell
response to cisplatin exposure.
2. Materials and methods
2.1. Cells, reagents and antibodies
Larynx-derived SCC-11 cell line (JHU-011 cell line, formerly
known as JHU-029 cell line, expressing wild type p53, wild type
p63 is ampliﬁed and DNp63a is overexpressed) was isolated from
primary tissue at the Head and Neck Cancer Research (HNCR)
Division (Johns Hopkins Medical Institutions (JHMI), and obtained
from the HNCR Tissue Bank as a gift by Dr. Joseph A. Califano. Using
the knock-in technology we generated cisplatin-sensitive SCC-11
cells (expressing wild type DNp63a protein) and cisplatin-
resistant SCC-11M cells (expressing DNp63a-S385G protein with
an impaired site for ATM kinase phosphorylation) [15]. Tongue-
derived SCC-25 cells (sensitive to cisplatin) and SCC-25CP cells
(with a spontaneously acquired cisplatin resistance) were obtained
from Dr. J.S. Lazo, as reviewed in [18,20].
Cells were incubated with control medium or 10 lg/ml cisplatin
(P4394, Sigma–Aldrich). To inhibit RIPK1 and mixed lineage kinase
domain-like (MLKL) activities, we used Necrostatin-1 (NEC-1,
N9037, Sigma–Aldrich, 30 lM, 1 h, serum-free media) and necro-
sulfonamide (NSA, C6327-2s, Cellagen Technology, 1 lM, 16 h),
respectively. We used antibodies against CASP8 (C7849, 1:1000,
Sigma–Aldrich), cylindromatosis (CYLD) (PAI-41097, 1:250),
death-assocated protein (DAP3) (MA1-41279, 1:150), and DAPK2
(PA5-19961, 1:500), all obtained from Thermo Scientiﬁc-Pierce.
We also used antibodies against a-tubulin (ab7291, 1:5000),
RIPK3 (ab56164, 1:500), MLKL (ab172868, 1:1000), and p-S358-
MLKL (ab187091, 1:1000), all purchased from Abcam, and ﬁnally
antibody against RIPK1 (NB100-56160, 1:1000, Novus
Biologicals). Goat anti-rabbit (AP307P), and goat anti-mouse
(AP181P) horseradish peroxidase-conjugated immunoglobulins
(IgG) were purchased from EMD-Millipore, and diluted at
1:5000–1:10000].
2.2. Immunoblotting and immunoprecipitation
Cells were lysed in buffer A (100 mM Tris–HCl, pH 7.5, 150 mM
NaCl, 2 mM EDTA, 0.5% Triton X-100, 0.5% Brij-50, 1 mM PMSF,
4 lg/ml aprotinin, 1 lg/ml pepstatin A, 1 lg/ml leupeptin, 1 mMNa3VO4, 50 mM NaF), sonicated ﬁve times for 10 s, and clariﬁed
for 30 min at 15000g [21]. Total lysate supernatants were
resolved by a 4–10% SDS–PAGE and analyzed by immunoblotting
after transfer onto PVDF membranes overnight. Membranes were
blocked with 10% fat-free milk with 0.1% Tween-20 in Tris-buffered
saline (TBS) and incubatedwith primary antibodies for 1 h in 3% fat-
free milk, 0.1% Tween-20 in TBS and after washing were incubated
with secondary antibodies for an additional 1 h at room tempera-
ture. Immunoreactive bands were visualized using an enhanced
chemiluminescence kit with the SuperSignal West Pico
Chemiluminescent Substrate (Pierce-Thermo Scientiﬁc). For
immunoprecipitation, total lysate supernatants were pre-incu-
bated with 10 ll of normal rabbit serum (R9133, Sigma) or normal
mouse serum (M5905, Sigma) for 30 min and then incubated with
50 ll of protein A-Sepharose 4B for an additional 30 min.
Following centrifugation, 500 ll of pre-cleared supernatant was
incubated with 10 lg of primary antibodies for 2 h at room temper-
ature and then with 40 ll of a 50% suspension of goat anti-rabbit
IgG-bound agarose (ab97052, Abcam) or goat anti-mouse IgG-
bound agarose (ab97025, Abcam) overnight at 4 C, and then was
washed three times with 1 ml of cold buffer A. Resulting samples
were boiled with SDS and b-mercaptoethanol, fractionated by a
SDS–PAGE and transferred onto PVDFmembranes for immunoblot-
ting, as mentioned above [21]. Blots were scanned and quantiﬁed
by the Image Quant software version 3.3 (Molecular Dynamics).
Values were normalized for the a-tubulin levels and expressed as
percentage of a control sample (deﬁned as 1).
2.3. Transfections and luciferase reporter assays
For microRNA/30-UTR luciferase reporter assays, we used the
control (empty) pLightSwitch_3UTR vector (S890005), the 30-UTR
luciferase reporter plasmids for CASP8 (S808083), MLKL
(S805840), DAP3 (S802569), DAPK2 (S809711), RIPK1 (S810475),
all were obtained from SwitchGear Genomics (SGG). The 30-UTR
reporter plasmid for CYLD (MiUTR1H-02603) was from Creative
Biogene. Cells (40–50% conﬂuency) in a 24-well plate were trans-
fected with the selected 30-UTR plasmids (0.1 lg), and RenSP
Renilla luciferase plasmid (0.01 lg) using a Fugene HD reagent
(Roche) for 36 h according to the manufacturer’s (SGG) recommen-
dations. Cells were also transfected for 36 h with the following
human mirVana mimics (at a ﬁnal concentration 50 nM): hsa-
miR-485-5p (MC10837), hsa-miR-221-3p (MC10337), hsa-miR-
214-3p (MC12124), hsa-miR-155-5p (MC12601), hsa-miR-22-3p
(MC10203), hsa-miR-101-3p (MC11414), and inhibitor for hsa-
miR-101-3p (AM11414), as well as with the scrambled RNA
(mirVana™ miRNA Mimic, Negative Control #1, 4464061, or
mirVana™ miRNA Inhibitor, Negative Control #1, 4464078), all
purchased from Ambion/Life Technologies.
Transfection efﬁciency was validated using the gWiz High-
Expression GFP vector (P040400, Genlantis), as recommended by
Roche. Resulting cells were treated with control media or 10 lg/
ml cisplatin for an additional 16 h. The LightSwitch Luciferase
Assay Kit (SwitchGear Genomics) was used to monitor a RenSP
Renilla luciferase reporter activity at 480 nm using a luminometer.
A total GFP ﬂuorescence was measured (linear curve was gener-
ated with the increasing concentrations of the GFP plasmid) using
a ﬂuorescence plate reader. Luciferase activity of each sample was
measured and corrected for total GFP. Each experiment was per-
formed 3 times in triplicate. Data presented as relative values
(RU) to data obtained from the control samples (cells transfected
with the scrambled RNA and exposed to control media), which des-
ignated as 1.
To generate the mutated 30-UTR plasmids with altered
microRNA ‘target’ sequences, we used a QuikChange Site-
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Fig. 1. Schematic representation of the microRNA-regulated targets involved in necroptotic pathway. The microRNAs induced by p-DNp63a (SCC-11 vs. SCC-11M) indicated
in black, while the repressed microRNAs indicated in gray (SCC-11 vs. SCC-11M) deﬁned by the MicroRNA Target Prediction And Functional Study Databases (see
Supplemental info). The corresponding microRNAs are shown next to the speciﬁc protein target. MicroRNAs listed next to ATM or DNp63a are shown to be inhibitors of ATM
or DNp63a.
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plate and 125 ng of each primer (see Supplemental methods). All
mutated plasmids were veriﬁed by sequencing at the Johns
Hopkins Synthesis and Sequencing core facility to conﬁrm the
presence of mutations.
In other experiments, cells (40–50% conﬂuency)/in 6-well plate
were also transfected with the 20 nM (ﬁnal concentration) of the
scrambled siRNA (Silencer Negative Control No. 1 siRNA,
AM4636) and RIPK1 siRNA (Silencer, #137228-137230, Life
Technologies) using 5–10 ll of Lipofectamine-2000 reagent
(Invitrogen/Life Technologies) for 36 h. Transfection efﬁciency
was validated using a Silencer Cy™ 3-labeled Negative Control
No. 1 siRNA (AM4621, Life Technologies), as recommended by a
manufacturer. Post-transfection, cells were exposed to control
medium and 10 lg/ml cisplatin for an additional 16 h. Each exper-
iment was performed 3 times in triplicate.
2.4. Cell viability assay
Cells/in 96-well plates were incubated in serum-free medium
with 5 lg/ml of the 3-(4,5-dimethyl thiazol-2-yl)-2,5-diphenyl
tetrazolium bromide (MTT assay, American Tissue Culture
Collection, ATCC 30-1010K) in the dark at 37 C for 4 h. Lysed cells
were incubated at 37 C for 2 h and the measurements (A570 nm to
A650 nm) were obtained on a Spectra Max 250 plate reader
(Molecular Devices). Each assay was repeated three times in
triplicate.
2.5. Statistical analysis
Difference between two groups or more than two groups was
performed by Student’s t-test, and one-way ANOVA test. The levels
of signiﬁcance were set to P 6 0.05.3. Results
Based on microRNA chip analysis [16,18] and using the web-
based microRNA target prediction databases (see Supplemental
methods), we deﬁned in silico targets for speciﬁc microRNAs down-
regulated (marked in gray) and upregulated (marked in black) in
SCC-11 cells compared to SCC-11M cells (Fig. 1). Some of these pre-
dicted protein targets are implicated in regulation of necroptotic
program of tumor cell death [1–3]. Using the 30-UTR-mediated
luciferase activity assay and immunoblotting analysis, we showed
that the tested microRNA mimics (e.g. miR-48-5p, miR-221-3p,
miR-101-3p, miR-22-3p, miR-155-5p, and miR-214-3p) markedly
(by 54–62%) modulated the luciferase reporter activities driven
by certain mRNA 30-UTR plasmids (Fig. 2A). However, these
microRNA mimics failed to inhibit the luciferase activities driven
by the 30-UTR plasmids whose microRNA ‘target’ sequences were
mutated (Fig. 2A, Table S1, Supplemental methods). Moreover,
tested microRNA mimics variably modulated the levels of CASP8,
CYLD, RIPK1, MLKL, DAP3, and DAPK2 proteins involved in necrop-
totic pathway (Fig. 2B).
We further found that the levels of endogenous CYLD, RIPK1,
MLKL, and DAP3 proteins were markedly higher in cisplatin-trea-
ted sensitive SCC-11 cells and SCC-25 cells than in cisplatin-treated
resistant SCC-11M cells and SCC-25CP cells, respectively (Fig. 3A).
However, the CASP8 protein levels in SCC-11/SCC-25 cells was
lower than in SCC-11M/SCC-25CP cells (Fig. 3A). We then exam-
ined the ability of RIPK1, RIPK3 and p-MLKL to form protein com-
plexes in sensitive (SCC-11 and SCC-25) cells and resistant (SCC-
11M and SCC-25CP) cells upon cisplatin exposure. Intriguingly,
we observed that the formation of RIPK1/RIPK3/p-MLKL protein
complexes occurred in sensitive SCC-11 and SCC-25 cells, while it
markedly decreased in resistant SCC-11M and SCC-25CP cells
(Fig. 3B).
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Fig. 2. DNp63a-dependent microRNA modulate their mRNA targets in vitro. (A) MicroRNA/30-UTR luciferase reporter assays for indicated targets in SCC-11 cells exposed to
control medium. Target protein symbols are indicated above the graph, while speciﬁc microRNA mimics are indicated below the graph. As a negative control, scrambled RNA
was used. All indicated 30-UTR plasmids were also mutated in the microRNA ‘target’ sites (as described in Supplemental methods and Table S1), and designated as Mut.
Experiments were run three times in triplicates and compared to data obtained with SCC-11 cells transfected with the scrambled RNA (*, P < 0.05). (B) Immunoblotting with
the indicated antibodies. Each blot was ﬁrst probed with indicated antibodies and after stripping with an antibody to a-tubulin used as a loading control. Lines between blots
indicate the separate gel runs. Blots were scanned and quantiﬁed in triplicate. Values (shown above the blots) normalized by a-tubulin levels were expressed as a fold change
to a scrambled control deﬁned as 1.
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miR-101-3p, a potential regulator of RIPK1, at the lower level than
resistant cells (SCC-11M and SCC-25CP) upon cisplatin exposure
[16,18]. We examined whether the inactivation of the key regula-
tor of necroptotic signaling RIPK1 using miR-101-3p mimic and
RIPK1 siRNA would affect a viability of sensitive SCC-11 cells and
SCC-25 cells. In addition we examined whether the miR-101-3p
inhibitor would affect a viability of resistant SCC-11M cells and
SCC-25CP cells. We thus observed that both SCC-11 cells and
SCC-25 cells were shown to markedly decrease their viability upon
cisplatin exposure compared to control media treatment (Fig. 4).
Both miR-101-3p mimic and RIPK1 siRNA partially increased the
resistance of sensitive SCC cells to cisplatin treatment (Fig. 4).
Inhibitory effect of miR-101-3p and RIPK1 siRNA on the RIPK1 pro-
tein levels in SCC cells was shown in Fig. S1A. Similarly, the necro-
statin (NEC-1, inhibitor of RIPK1) and necrosulfonamide (NSA,
MLKL inhibitor) increased the viability of SCC-11 cells and SCC-
25 cells upon cisplatin exposure (Fig. 4) suggesting a potential role
for a necroptotic pathway in the SCC-11/SCC-25 cell response tocisplatin treatment. The RIPK1 protein levels were not affected
by the treatment of SCC cells with NEC-1 and NSA (Fig. S1B).
However, the miR-101-3p inhibitor increased the RIPK1 level in
resistant SCC-11M cells and SCC-25CP cells (Fig. S1C), and sensitiv-
ity of SCC-11M cells and SCC-25CP cells to cisplatin exposure
(Fig. 4).4. Discussion
The exposure of tumor cells to anti-cancer chemotherapeutic
compounds was shown to induce DNA damage signaling subse-
quently leading to cell cycle arrest, apoptosis, autophagy and
necroptosis ultimately resulting in tumor cell death [1–5].
However, these treatments are often result in tumor cell resistance,
which involve multiple molecular mechanisms ranging from epi-
genetic deregulation, alterations in apoptosis and autophagy and
even metabolic changes between tumor cells sensitive and resis-
tant to acquire cell death phenotype [1–5,8–14].
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through a RIPK1- and/or RIPK3-dependent pathway [2–6,22].
Other death receptors (e.g. CD95, TRAIL, etc.), as well as TNF-re-
lated weak inducer of apoptosis, lymphotoxin b, and ectodermal
dysplasia receptor could also trigger this pathway [2–7,22].
Furthermore, different kinds of physical–chemical stress stimuli
can initiate necroptosis, including reactive oxygen species, DNA
damaging anticancer drugs, and ionizing radiation [2–6,23].Binding of the TNFR1 by TNFa leads to recruitment of various
proteins, such as tumor necrosis factor receptor type 1-associated
death domain protein (TRADD), RIPK1, cIAP proteins, TRAF-2, and
-5 into a multimeric protein complex called TNFR1 complex [2–
7,24–26]. Within this complex, RIPK1 is polyubiquitinated by
cIAP proteins leading to the activation of the NF-jB [27,28]. TNF
receptor (TNFR) is then rapidly internalized upon ligand binding
resulting in alterations in the posttranslational modiﬁcations of
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scrambled (Scr) RNA, miR-101-3p mimic and siRNA against RIPK2. SCC-11M cells
were transfected with the Scr RNA and miR-101-3p inhibitor. After 36 h post-
transfection, cells were exposed to control media (Con) and 10 lg/ml cisplatin (CIS)
for 16 h. SCC-11 cells were also treated with the RIPK1 inhibitor, necrostatine (NEC-
1), and MLKL inhibitor, necrosulfonamide (NSA). (B) SCC-25 cells were transfected
with the Scr RNA, miR-101-3p mimic and siRNA against RIPK2. SCC-25CP cells were
transfected with the Scr RNA and miR-101-3p inhibitor. After 36 h post-transfec-
tion, cells were exposed to control media (Con) and 10 lg/ml cisplatin (CIS) for 16 h.
SCC-25 cells were also treated with the RIPK1 inhibitor, necrostatine (NEC-1), and
MLKL inhibitor, necrosulfonamide (NSA). All cells were also exposed to control
media (Con) and 10 lg/ml cisplatin (CIS) for 16 h, as indicated. Cell viability assay.
Assay was performed using ﬁve independent experiments in triplicate and
compared to control conditions (*, P < 0.05).
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CYLD, which in turn increases the RIPK1 protein level [28,29].
When CASP8 is inhibited or downregulated, RIPK1 increases its
ability to form a complex with RIPK3 triggering the necroptotic
pathway [30]. This RIPK1/3 cytoplasmic protein complex ‘‘necro-
some’’ involves the reciprocal phosphorylation of RIPK1 and
RIPK3 resulting in MLKL phosphorylation [24–28]. The latter plays
a decisive role in the transduction of the necroptotic signal to cell
death [31,32].
A number of anti-cancer drugs have been shown to initiate
necroptosis in cancer cells [33–38]. Shikonin, a naturally occurring
naphthoquinone, has been reported inducing a necroptotic cell
death in drug- and apoptosis-resistant cancer cells [34].
Staurosporine, an inhibitor of protein kinases, triggers necroptosis
in leukemia cells when caspase activation is blocked, and the
necroptotic pathway was inhibited by the RIPK1 inhibitor, NEC-1,
and MLKL inhibitor, NSA [35]. Obatoclax, an inhibitor ofanti-apoptotic BCL2 proteins, was shown to induce autophagy-de-
pendent necroptosis in glucocorticoid-resistant acute lymphoblas-
tic leukemia [37]. Obatoclax was also shown to trigger a physical
interaction of ATG5 (a component of autophagosomal membranes)
with the key regulators of the ‘‘necrosome’’, RIPK1 and RIPK3 [37].
Our previous reports have shown that the exposure of head and
neck SCC-11 cells to cisplatin induced the phosphorylation of
DNp63a by the ATM kinase [15]. However, the knock-in alteration
of the ATM target site in the DNp63a protein (S385 to G385)
diminished the ability for mutated DNp63a to be phosphorylated
in SCC-11M cells [15]. We have found that the wild type
DNp63a (p-DNp63a) and mutated DNp63a (non-p-DNp63a) dif-
ferentially regulate the expression of speciﬁc microRNAs in SCC-
11 cells and SCC-11M cells suggesting that the levels of these
microRNA protein targets might be also affected [16]. We have
observed that the DNp63a-responsive microRNAs are very likely
to modulate the protein targets involved in cell cycle arrest, apop-
tosis, and autophagy, and even epigenetic regulation [16–18,20].
Since p63 was previously shown to transcriptionally activate
the expression of several death domain receptors involved in TNF
signaling [13], we explored a potential role for DNp63a in regula-
tion of necroptotic pathway. We observed that a few DNp63a-
responsive microRNAs might act as regulators of proteins
implicated in the necroptotic signaling. We showed that the speci-
ﬁc microRNAs (miR-485-5p, miR-221-3p, miR-101-3p, miR-22-3p,
miR-155-5p, and miR-214-3p) modulated the luciferase activities
driven by the CASP8, CYLD, RIPK1, MLKL, DAP3, and DAPK2 30-
UTRs in vitro. We further showed that the endogenous CYLD,
RIPK1, MLKL, DAP3, and DAPK2 protein levels were higher in sen-
sitive SCC cells (SCC-11, SCC-25) than in resistant SCC cells (SCC-
11M, SCC-25CP). However, the CASP8 protein levels were lower
in sensitive SCC cells than in resistant SCC cells. We next showed
that the cisplatin exposure led to a varied formation of response
in the RIPK1/RIPK3/p-MLKL complex in sensitive and resistant
SCC cells. We observed a higher degree of the complex formation
in sensitive SCC cells than in resistant SCC cells. We ﬁnally
observed that the viability of SCC cells sensitive and resistant to
cisplatin treatment could be potentially altered using the miR-
101-3p mimic or inhibitor, as well as with RIPK1 siRNA, and
necroptotic inhibitors. We found that the miR-101-3p mimic could
increase the resistance of sensitive SCC cells to cisplatin, while the
miR-101-3p inhibitor increased the sensitivity of resistant SCC
cells to the drug. Overall, these data suggests a potential involve-
ment of necroptotic pathway in SCC cell response to cisplatin
exposure supporting the previous report showing necroptosis in
cisplatin- and inhibitor of apoptosis (IAP) antagonist-resistant
ovarian carcinomas [36].
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